All
costs were calculated in 2005 US dollars and were reported as
US dollars and Egyptian pounds (LE) with use of an exchange
rate of 5.79 LE to each US dollar. A 3% annual discount rate
was used to adjust for medical costs associated with rotavirus
disease that would have occurred during the future 5 years. In
addition to absolute cost savings, we calculated a benefit-cost
ratio (BCR), defined as the present value of the benefits of the
vaccination program divided by the present value of the cost
of implementing the expanded vaccination program.